Kissei Pharmaceutical Co., Ltd.
【Kissei Pharmaceutical】Safety Information Flash and Reminder for Medicinal Products｜May 2026
Kissei Pharmaceutical revised the package insert regarding liver function disorder for the therapeutic drug Tabneuvos and issued a safety information flash to alert healthcare professionals. The company requests caution in using the drug for new patients and thorough liver function testing for ongoing patients. The impact on financial performance is currently uncertain.
Key Figures
- Unknown
- Unknown
- Unknown
AI要約
Safety Information and Package Insert Revision
Kissei Pharmaceutical has revised the package insert concerning liver function disorder to enhance the safety of the designated intractable disease treatment drug Tabneuvos, and has called on healthcare professionals to avoid using the drug for new patients and to conduct thorough liver function tests. This revision aims to address the risk of severe liver function disorder and ensure patient safety. The revision was implemented on May 15, 2026, and a safety information flash was also issued to raise awareness.
Future Actions and Impact on Performance
The company is currently reviewing the potential impact of this matter on its financial performance and will disclose findings promptly once determined. It is focusing on providing proper information and guidance to healthcare professionals and patients to promote safe drug use. The company continues to strive for safety in medical practice and the health of patients and is monitoring the potential impact on earnings.
Kissei Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
